Vor Biopharma to be Delisted from Nasdaq
Ticker: VOR · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: VOR
TL;DR
Nasdaq's kicking VOR off the exchange, effective tomorrow.
AI Summary
Vor Biopharma Inc. announced on August 29, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company has been notified that its common stock will be delisted from the Nasdaq Capital Market, effective August 30, 2024, due to failure to meet continued listing requirements.
Why It Matters
This delisting signifies a significant setback for Vor Biopharma, potentially impacting its ability to raise capital and its stock's liquidity.
Risk Assessment
Risk Level: high — Delisting from a major exchange like Nasdaq poses significant financial and operational risks for a company.
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange issuing delisting notice
- Nasdaq Capital Market (company) — Specific market for delisting
- August 29, 2024 (date) — Date of notice
- August 30, 2024 (date) — Effective date of delisting
FAQ
What is the primary reason for Vor Biopharma's delisting from Nasdaq?
Vor Biopharma received a notice from the Nasdaq Stock Market indicating non-compliance with continued listing requirements, leading to the decision for delisting.
When will Vor Biopharma's common stock be delisted from the Nasdaq Capital Market?
The delisting is effective as of August 30, 2024.
What specific Nasdaq market is Vor Biopharma being delisted from?
Vor Biopharma's common stock will be delisted from the Nasdaq Capital Market.
What is the date of the report filed by Vor Biopharma?
The Form 8-K report was filed as of August 30, 2024, with the earliest event reported on August 29, 2024.
What is Vor Biopharma's principal executive office address?
Vor Biopharma's principal executive offices are located at 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts, 02140.
Filing Stats: 743 words · 3 min read · ~2 pages · Grade level 13.5 · Accepted 2024-08-30 16:01:53
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
- $1.00 — e Company's common stock has been below $1.00 per share for 30 consecutive business d
Filing Documents
- d885644d8k.htm (8-K) — 25KB
- 0001193125-24-211050.txt ( ) — 147KB
- vor-20240829.xsd (EX-101.SCH) — 3KB
- vor-20240829_lab.xml (EX-101.LAB) — 18KB
- vor-20240829_pre.xml (EX-101.PRE) — 11KB
- d885644d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: August 30, 2024 By: /s/ Robert Ang Robert Ang Chief Executive Officer